The data presented here leverage prior work indicating that [18F]FTT PET can measure regional PARP expression (6, 7) and demonstrate that uptake in breast cancer decreased to background after introducing a pharmacologic PARPi, building on in vitro assays supporting the use of [18F]FTT PET as a measure of drug-target engagement. This evidence concerns the gene PARP1 and breast carcinoma.